



#15
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Jackowski et al. JUN 26 2003
Serial No. : 09/845,726 TECH CENTER 1600/2900
Filed : April 30, 2001
For : Biopolymer Marker Indicative
Of Disease State Having A
Molecular Weight of 1424
Daltons
Examiner : Nguyen, Bao-Thuy L.
Art Unit : 1641
Our File No. : 2132.033

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on 16-19-03

Susan Hess

To: Mail Stop: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR § 1.132

I, Ferris H. Lander, do hereby declare as follows:

1. I am a registered Patent Agent and am authorized to
represent the inventor's and assignee in the application
entitled "Biopolymer Marker Indicative Of Disease State Having A
Molecular Weight of 1424 Daltons", having U.S. Application
Serial No. 09/845,726, filed April 30, 2001.

2. In order to provide data which would obviate any
rejection/objection regarding completeness of the disclosure, I
contacted Dr. George Jackowski, Chairman and Chief Science

Officer of Syn-x Pharma Inc., and asked to be provided with evidence of the absence of the 1424 dalton marker (amino acid residues 2-12 of SEQ ID NO:1) in normal human sera.

3. This declaration (including the attached figure) is provided in order to show a comparison of the indicated disease marker (the 1424 dalton marker; amino acid residues 2-12 of SEQ ID NO:1) to a normal/control group, so as to evidence that the marker is not present in normal human sera.

4. The attached figure, obtained from Dr. Jackowski, provides side-by-side profiles (obtained using techniques of mass spectrometry) of normal human sera versus sera from congestive heart failure patients. This profile comparison clearly evidences the absence of the 1424 dalton marker (amino acid residues 2-12 of SEQ ID NO:1) in normal human sera.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

6-19-2003

Date



Ferris H. Lander
Reg. No. 43,377

\\\Ns2\DRV_E\STAFF DATA FILES\Ferris Lander's Files\FL\AMENDMNT.PAT\2132_033.132.wpd



CHF

NHS



in order to be accurate must be reproducible